More evidence about how a patient’s genetic make-up can effect how well they react to treatment:
Genetic Variations Influence Patient Response to Treatment for Multiple Myeloma: Presented at EHA By Jenny Powers for Doctor’s Guide
BARCELONA, Spain — June 16, 2010 — The response to standard therapeutics used for the treatment of patients with multiple myeloma (MM) is tempered by genetic variations in drug metabolism, inflammatory response, and DNA repair, researchers said here at the 15th Congress of the European Hematology Association (EHA).
Sophie Corthals, MD, Erasmus University Medical Center, Rotterdam, the Netherlands, presented the findings here on June 13.
The study was prompted by the observation that patients with MM who are treated with thalidomide plus melphalan experience improved overall response and progression-free survival (PFS), but not increased overall survival (OS) because of relapse-associated inferior survival.
Researchers collected peripheral white blood cell DNA from 532 patients with MM who participated in a trial comparing vincristine/doxorubicin/dexamethasone (VAD) with thalidomide plus doxorubicin and dexamethasone (TAD).
Genetic variations were analysed by a custom-built molecular inversion probe (MIP) single-nucleotide polymorphism (SNP) chip that contained 3,404 SNPs selected in “functional regions” within 983 genes that represent cellular functions and pathways thought to influence disease response, toxicities, complications, and survival.
The responses to both TAD and VAD treatment were associated with the drug absorption, distribution, metabolism, and excretion (ADME) genes ABCC1 and ABCC, as demonstrated by SNP association analyses.
Doctor’s Guide (DocGuide.com), an interactive video Website for physicians, features lots of technical information about multiple myeloma. Go to the Doctor’s Guide Myeloma Page to see more.
Feel good and keep smiling! Pat